Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...

The analyst points out that Eli Lilly’s success in this area is backed by several advantages that should help it maintain a leading position and market share in the furture. Even in Q4 2024 ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Eli Lilly and AstraZeneca (AZ ... which it will charge to earnings in Q4 2016. Details emerge about solanezumab failure in Alzheimer's The companies made the announcement as Lilly revealed ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY ... Lilly’s shares jumped 3.4% on Feb. 6 after the company reported Q4 2024 adjusted EPS of $5.32 and revenue of $13.5 billion ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...